Development of investigational radiation modifiers

A. Dimitrios Colevas, J. Martin Brown, Stephen Hahn, James Mitchell, Kevin Camphausen, C. Norman Coleman, Barbara Conley, Richard Cumberlin, Helen B. Stone, Rosemary Wong, Boris Freidlin, Ken Kobayashi, Anthony J. Murgo, Robert Shoemaker, Philip J. Tofilon, Hak Choy, Adam Dicker, James H. Doroshow, Silvia C. Formenti, Adam Garden & 12 others Stephen Gately, Richard Hill, Timothy J. Kinsella, Malcolm Moore, Jann Sarkaria, Dietmar Siemann, Gerald Sokol, Beverly A. Teicher, Andy Trotti, Andrew T. Turrisi, Raul Urtasun, Everett E. Vokes

Research output: Contribution to journalArticle

Abstract

Positive, appropriate, preclinical data that are adequately reviewed are a prerequisite for clinical trials of radiation modifiers. The appropriate tumor models, dosing schedules, and assays should be based on the mechanism of action of the proposed radiation modifier. The activity of a radiation modifier should be correlated with its activity against a target. Priority for clinical development should be given to agents that have known, assay-able targets or that produce extraordinary preclinical efficacy data. Phase I trials of radiation modifiers with radiation should efficiently and safely determine a recommended phase II dose. The recommended phase II dose for radiation modifier plus radiation trials is not necessarily the maximum tolerated dose of the combination, nor is it necessarily related to the recommended phase II dose of the agent alone or in combination with other drugs. The schedule of the combination of radiation modifier and radiation should be based on preclinical optimization experiments. Clinically useful endpoints in radiation modifier plus radiation trials usually include time to progression, locoregional control, and survival rather than overall response rates. Clinical development of radiation modifiers plus radiation should consist of building the radiation modifier into acceptable standard of care regimens utilizing full-dose radiation.

Original languageEnglish (US)
Pages (from-to)646-651
Number of pages6
JournalJournal of the National Cancer Institute
Volume95
Issue number9
StatePublished - May 7 2003
Externally publishedYes

Fingerprint

Radiation
Appointments and Schedules
Maximum Tolerated Dose
Standard of Care
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colevas, A. D., Brown, J. M., Hahn, S., Mitchell, J., Camphausen, K., Coleman, C. N., ... Vokes, E. E. (2003). Development of investigational radiation modifiers. Journal of the National Cancer Institute, 95(9), 646-651.

Development of investigational radiation modifiers. / Colevas, A. Dimitrios; Brown, J. Martin; Hahn, Stephen; Mitchell, James; Camphausen, Kevin; Coleman, C. Norman; Conley, Barbara; Cumberlin, Richard; Stone, Helen B.; Wong, Rosemary; Freidlin, Boris; Kobayashi, Ken; Murgo, Anthony J.; Shoemaker, Robert; Tofilon, Philip J.; Choy, Hak; Dicker, Adam; Doroshow, James H.; Formenti, Silvia C.; Garden, Adam; Gately, Stephen; Hill, Richard; Kinsella, Timothy J.; Moore, Malcolm; Sarkaria, Jann; Siemann, Dietmar; Sokol, Gerald; Teicher, Beverly A.; Trotti, Andy; Turrisi, Andrew T.; Urtasun, Raul; Vokes, Everett E.

In: Journal of the National Cancer Institute, Vol. 95, No. 9, 07.05.2003, p. 646-651.

Research output: Contribution to journalArticle

Colevas, AD, Brown, JM, Hahn, S, Mitchell, J, Camphausen, K, Coleman, CN, Conley, B, Cumberlin, R, Stone, HB, Wong, R, Freidlin, B, Kobayashi, K, Murgo, AJ, Shoemaker, R, Tofilon, PJ, Choy, H, Dicker, A, Doroshow, JH, Formenti, SC, Garden, A, Gately, S, Hill, R, Kinsella, TJ, Moore, M, Sarkaria, J, Siemann, D, Sokol, G, Teicher, BA, Trotti, A, Turrisi, AT, Urtasun, R & Vokes, EE 2003, 'Development of investigational radiation modifiers', Journal of the National Cancer Institute, vol. 95, no. 9, pp. 646-651.
Colevas AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN et al. Development of investigational radiation modifiers. Journal of the National Cancer Institute. 2003 May 7;95(9):646-651.
Colevas, A. Dimitrios ; Brown, J. Martin ; Hahn, Stephen ; Mitchell, James ; Camphausen, Kevin ; Coleman, C. Norman ; Conley, Barbara ; Cumberlin, Richard ; Stone, Helen B. ; Wong, Rosemary ; Freidlin, Boris ; Kobayashi, Ken ; Murgo, Anthony J. ; Shoemaker, Robert ; Tofilon, Philip J. ; Choy, Hak ; Dicker, Adam ; Doroshow, James H. ; Formenti, Silvia C. ; Garden, Adam ; Gately, Stephen ; Hill, Richard ; Kinsella, Timothy J. ; Moore, Malcolm ; Sarkaria, Jann ; Siemann, Dietmar ; Sokol, Gerald ; Teicher, Beverly A. ; Trotti, Andy ; Turrisi, Andrew T. ; Urtasun, Raul ; Vokes, Everett E. / Development of investigational radiation modifiers. In: Journal of the National Cancer Institute. 2003 ; Vol. 95, No. 9. pp. 646-651.
@article{801e12d48e8f4fadbf3d2e7f9e33721b,
title = "Development of investigational radiation modifiers",
abstract = "Positive, appropriate, preclinical data that are adequately reviewed are a prerequisite for clinical trials of radiation modifiers. The appropriate tumor models, dosing schedules, and assays should be based on the mechanism of action of the proposed radiation modifier. The activity of a radiation modifier should be correlated with its activity against a target. Priority for clinical development should be given to agents that have known, assay-able targets or that produce extraordinary preclinical efficacy data. Phase I trials of radiation modifiers with radiation should efficiently and safely determine a recommended phase II dose. The recommended phase II dose for radiation modifier plus radiation trials is not necessarily the maximum tolerated dose of the combination, nor is it necessarily related to the recommended phase II dose of the agent alone or in combination with other drugs. The schedule of the combination of radiation modifier and radiation should be based on preclinical optimization experiments. Clinically useful endpoints in radiation modifier plus radiation trials usually include time to progression, locoregional control, and survival rather than overall response rates. Clinical development of radiation modifiers plus radiation should consist of building the radiation modifier into acceptable standard of care regimens utilizing full-dose radiation.",
author = "Colevas, {A. Dimitrios} and Brown, {J. Martin} and Stephen Hahn and James Mitchell and Kevin Camphausen and Coleman, {C. Norman} and Barbara Conley and Richard Cumberlin and Stone, {Helen B.} and Rosemary Wong and Boris Freidlin and Ken Kobayashi and Murgo, {Anthony J.} and Robert Shoemaker and Tofilon, {Philip J.} and Hak Choy and Adam Dicker and Doroshow, {James H.} and Formenti, {Silvia C.} and Adam Garden and Stephen Gately and Richard Hill and Kinsella, {Timothy J.} and Malcolm Moore and Jann Sarkaria and Dietmar Siemann and Gerald Sokol and Teicher, {Beverly A.} and Andy Trotti and Turrisi, {Andrew T.} and Raul Urtasun and Vokes, {Everett E.}",
year = "2003",
month = "5",
day = "7",
language = "English (US)",
volume = "95",
pages = "646--651",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Development of investigational radiation modifiers

AU - Colevas, A. Dimitrios

AU - Brown, J. Martin

AU - Hahn, Stephen

AU - Mitchell, James

AU - Camphausen, Kevin

AU - Coleman, C. Norman

AU - Conley, Barbara

AU - Cumberlin, Richard

AU - Stone, Helen B.

AU - Wong, Rosemary

AU - Freidlin, Boris

AU - Kobayashi, Ken

AU - Murgo, Anthony J.

AU - Shoemaker, Robert

AU - Tofilon, Philip J.

AU - Choy, Hak

AU - Dicker, Adam

AU - Doroshow, James H.

AU - Formenti, Silvia C.

AU - Garden, Adam

AU - Gately, Stephen

AU - Hill, Richard

AU - Kinsella, Timothy J.

AU - Moore, Malcolm

AU - Sarkaria, Jann

AU - Siemann, Dietmar

AU - Sokol, Gerald

AU - Teicher, Beverly A.

AU - Trotti, Andy

AU - Turrisi, Andrew T.

AU - Urtasun, Raul

AU - Vokes, Everett E.

PY - 2003/5/7

Y1 - 2003/5/7

N2 - Positive, appropriate, preclinical data that are adequately reviewed are a prerequisite for clinical trials of radiation modifiers. The appropriate tumor models, dosing schedules, and assays should be based on the mechanism of action of the proposed radiation modifier. The activity of a radiation modifier should be correlated with its activity against a target. Priority for clinical development should be given to agents that have known, assay-able targets or that produce extraordinary preclinical efficacy data. Phase I trials of radiation modifiers with radiation should efficiently and safely determine a recommended phase II dose. The recommended phase II dose for radiation modifier plus radiation trials is not necessarily the maximum tolerated dose of the combination, nor is it necessarily related to the recommended phase II dose of the agent alone or in combination with other drugs. The schedule of the combination of radiation modifier and radiation should be based on preclinical optimization experiments. Clinically useful endpoints in radiation modifier plus radiation trials usually include time to progression, locoregional control, and survival rather than overall response rates. Clinical development of radiation modifiers plus radiation should consist of building the radiation modifier into acceptable standard of care regimens utilizing full-dose radiation.

AB - Positive, appropriate, preclinical data that are adequately reviewed are a prerequisite for clinical trials of radiation modifiers. The appropriate tumor models, dosing schedules, and assays should be based on the mechanism of action of the proposed radiation modifier. The activity of a radiation modifier should be correlated with its activity against a target. Priority for clinical development should be given to agents that have known, assay-able targets or that produce extraordinary preclinical efficacy data. Phase I trials of radiation modifiers with radiation should efficiently and safely determine a recommended phase II dose. The recommended phase II dose for radiation modifier plus radiation trials is not necessarily the maximum tolerated dose of the combination, nor is it necessarily related to the recommended phase II dose of the agent alone or in combination with other drugs. The schedule of the combination of radiation modifier and radiation should be based on preclinical optimization experiments. Clinically useful endpoints in radiation modifier plus radiation trials usually include time to progression, locoregional control, and survival rather than overall response rates. Clinical development of radiation modifiers plus radiation should consist of building the radiation modifier into acceptable standard of care regimens utilizing full-dose radiation.

UR - http://www.scopus.com/inward/record.url?scp=0038363472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038363472&partnerID=8YFLogxK

M3 - Article

VL - 95

SP - 646

EP - 651

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -